Targeted Cancer Therapy
We develop new tools and technologies to specifically eliminate tumor cells.
Some of these strategies are now being pursued and brought to clinical trials by our spin-off company Tubulis GmbH, Planegg-Martinsried, Germany: https://tubulis.com
LMU news:
LMU research transfer: several start-ups attract 7-figure investments (June 18th, 2024)
Research transfer: LMU spin-off Tubulis concludes partnership for the development of cancer drugs (April 27th, 2023)
We conjugate cytotoxins to antibodies generating so-called antibody drug conjugates (ADCs) (1) which bind to specific structures at the surface of cancer cells (2).
The cancer cells internalise these ADCs into endoscopes (3) which then turn into lysosomes (4) where the drugs are released and then attach vital cellular structures like microtubules (5).
Recent publication:
Roas M, Vick B, Kasper MA, Able M, Polzer H, Gerlach M, Kremmer E, Hecker JS, Schmitt S, Stengl A, Waller V, Hohmann N, Festini M, Ludwig AE, Rohrbacher L, Herold T, Subklewe M, Götze KS, Hackenberger CPR, Schumacher D, Helma-Smets J, Jeremias I, Leonhardt H and Spiekermann K (2023). Targeting FLT3 by new-generation antibody-drug-conjugate in combination with kinase inhibitors for treatment of AML. Blood, 141, 1023-1035. PubMed
Further publications see Google Scholar